logo
Share SHARE
FONT-SIZE Plus   Neg

Isotechnika Pharma Obtains Notice Of ILJIN's Request For Arbitration

Isotechnika Pharma Inc. (ISA.TO) announced that it has received notification that ILJIN Life Science Co., Ltd. has submitted a request for arbitration relating to Isotechnika's termination of their Development, Distribution and License Agreement or "DDL".

"We are confident that our termination of the original DDL is valid, and are prepared for arbitration proceedings. We plan on continuing to engage companies, including ILJIN, who have expressed interest in working with us to advance our lead program," said Robert Foster, Isotechnika's CEO.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
British lender Lloyds Banking Group Plc. Friday reported higher profit in its first half, benefited by increased net interest income and margin as well as lower impairment. Looking ahead, the company lifted its net interest margin forecast. Amgen reported an increase in second-quarter profit, driven by sales of arthritis drug Enbrel and osteoporosis treatments Xgeva and Prolia, and improved margins. Both earnings and sales topped Wall Street estimates. Electronic Arts Inc. (EA) on Thursday reported an increase in profit for the first quarter, reflecting continued strong digital revenues, with both earnings and revenues topping Wall Street estimates. However, shares of the company fell over 4 percent, after having detailed a weak outlook. Redwood...
comments powered by Disqus
Follow RTT